Andreas Halvorsen's position in BridgeBio Pharma is currently worth $962M. That's 2.71% of their equity portfolio (9th largest holding). The investor owns 9.72% of the outstanding BridgeBio Pharma stock. Andreas Halvorsen started to build up the position in BridgeBio Pharma in Q2 2019. Since then they sold 8.07M shares. The stake costed the investor $511M, netting the investor a gain of 88% so far.